Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with lewy bodies: Caveat for clinical use

Clinical Nuclear Medicine

Volumn 40, Issue 1, 2015, Pages 32-35

  Del Sole, Angelo ^a,b   Perini, Giulia ^c   Lecchi, Michela ^a,b   Mariani, Claudio ^c   Lucignani, Giovanni ^a,b   Clerici, Francesca ^c  

^a SAN PAOLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Dementia with Lewy bodies; Extrapyramidal signs; FP CIT; SPECT

Indexed keywords

IOFLUPANE I 123; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PUTAMEN; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; DIAGNOSTIC USE; EVALUATION STUDY; PATHOLOGY; SCINTISCANNING;

AGED; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84917690884     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000602     Document Type: Article

References (26)

1. Collerton D, Burn D, McKeith I, et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord. 2003;16:229-237.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65: 1863-1872.
3. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54: 1050-1058.
4. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology. 2004;63:975-982.
5. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
6. 123I-FP-CIT SPECT in possible dementiawith Lewy bodies. Br J Psychiatry. 2009;194:34-39.
7. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919-925.
8. Clerici F, Del Sole A, Chiti A, et al. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q J Nucl Med Mol Imaging. 2009;53:646-657.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
10. Fahn S, Elton R. Recent developments in Parkinson's disease. In: Fahn S, Marsden C, Goldstein M, et al., eds. Recent Developments in Parkinson's Disease. New York, NY: McMillan; 1987. 153-163.
11. Calvini P, Rodriguez G, Inguglia F, et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240-1253.
12. 123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213-227.
13. 123I]FPCIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40:565-573.
14. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(Suppl 7):S43-S51.
15. Walker Z, Costa DC,Walker RWH, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62: 1568-1572.
16. 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000; 15:692-698.
17. Walker Z, Jaros E, Walker RWH, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78: 1176-1181.
18. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology. 2000;54:1616-1625.
19. Ballard CG. Definition and diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004;17(Suppl 1):15-24.
20. Colloby SJ,McParland S, O'Brien JT, et al. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain. 2012; 135:2798-2808.
21. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2010;1184:188-195.
22. Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain. 2006;129: 729-735.
23. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun. 2007;28:511-519.
24. Borghammer P, Hansen SB, Eggers C, et al. Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol Scand. 2012;125: 303-310.
25. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 1997;49:717-723.
26. 123I-FPCIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. Parkinsonism Relat Disord. 2012;18:225-229.